Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - ropinirolum - compresse a rilascio modificati - ropinirolum 4 mg ut ropiniroli hydrochloridum, hypromellosum, lactosum monohydricum 44.04 mg, carmellosum natricum, ricini oleum hydrogenatum, maltodextrinum, magnesii stearas, silica colloidalis anhydrica, Überzug: hypromellosum, glyceroli dibehenas, mannitolum, povidonum k 29-32, magnesii stearas, silica colloidalis anhydrica, e 172 (flavum), Überzug: hypromellosum, macrogolum 400, e 110 1.24 mg, e 132, e 171, pro compresso obducto corresp. natrium 1.6 mg. - morbo di parkinson - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - ropinirolum - compresse a rilascio modificati - ropinirolum 8 mg ut ropiniroli hydrochloridum, hypromellosum, lactosum monohydricum 39.48 mg, carmellosum natricum, ricini oleum hydrogenatum, maltodextrinum, magnesii stearas, silica colloidalis anhydrica, Überzug: hypromellosum, glyceroli dibehenas, mannitolum, povidonum k 29-32, magnesii stearas, silica colloidalis anhydrica, e 172 (flavum), Überzug: hypromellosum, macrogolum 400, e 171, e 172 (rubrum), e 172 (nigrum), e 172 (flavum), pro compresso obducto corresp. natrium 1.6 mg. - morbo di parkinson - synthetika

Italia - italiano - myHealthbox

farmaroc - pentossifillina - compresse a rilascio modificato - 400mg - vasodilatatori periferici - ulcere venose croniche

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

gebro pharma ag - tramadoli hydrochloridum - compresse a rilascio modificati - tramadoli hydrochloridum 100 mg, poly(vinylis acetas), povidonum k 30, natrii laurilsulfas corresp. natrium ca. 0.09 mg, silica colloidalis anhydrica, xanthani gummi, hydroxypropylis diamyli phosphas, oleum vegetabile hydrogenatum, magnesii stearas, pro compresso. - analgesico - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

gebro pharma ag - tramadoli hydrochloridum - compresse a rilascio modificati - tramadoli hydrochloridum 200 mg, poly(vinylis acetas), povidonum k 30, natrii laurilsulfas corresp. natrium ca. 0.1 mg, silica colloidalis anhydrica, xanthani gummi, hydroxypropylis diamyli phosphas, oleum vegetabile hydrogenatum, magnesii stearas, pro compresso. - analgesico - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

gebro pharma ag - tramadoli hydrochloridum - compresse a rilascio modificati - tramadoli hydrochloridum 300 mg, poly(vinylis acetas), povidonum k 30, natrii laurilsulfas corresp. natrium ca. 0.14 mg, silica colloidalis anhydrica, xanthani gummi, hydroxypropylis diamyli phosphas, oleum vegetabile hydrogenatum, magnesii stearas, pro compresso. - analgesico - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - agenti antineoplastici - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Unione Europea - italiano - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - febbre emorragica di ebola - vaccini - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - tisagenlecleucelum car positive e vitali t-cellule. contiene cellule geneticamente modificate - zellsuspension zur infusione - beutel: tisagenlecleucelum car-positive lebensfähige t-zellen. enthält genetisch veränderte zellen 1,2x10e6–6,0x10e8 pro dosi, natrium, chloridum, magnesium, acetas, gluconas, glucosum, 5-hydroxymethylfurfuralum, albuminum, n-acetyltryptophanum natricum, caprylas, aluminium, dextranum 40, dimethylis sulfoxidum, dimethylis sulfonum, q.s. pro 50 ml. - 1) die behandlung von pädiatrischen und jungen erwachsenen patienten im alter bis zu 25 jahren mit akuter lymphatischer b-zell-leukämie (b-zell-all), die refraktär ist, nach einer transplantation rezidiviert ist oder nach zwei therapielinien oder später rezidiviert ist. 2) die behandlung erwachsener patienten mit rezidiviertem oder refraktärem diffus grosszelligem b-zell-lymphom (dlbcl) nach zwei oder mehr linien einer systemischen therapie. 3) behandlung erwachsener patienten mit rezidiviertem oder refraktärem follikulärem lymphom (fl) nach drei oder mehr linien einer systemischen therapie, - trapianto: gentherapieprodukt

Italia - italiano - Ministero della Salute

fatro s.p.a - vaccino a virus vivo attenuato e modificato della malattia di aujeszky - iniettabile - vaccino a virus vivo attenuato e modificato della malattia di aujeszky - immunologici per suini - suini - immunizzazione attiva nei suini all'ingrasso per prevenire la mortalità ed i segni clinici dovuti alla malattia di aujeszky e per ridurre la diffusione del virus della malattia di aujeszky.